Close Menu

Oxford BioDynamics

The partners aim to identify signatures to predict the severity of disease in those infected and determine how patients will respond to therapies.

The UK-based company's revenues are generated exclusively from epigenetic biomarker research and development alliances with commercial and academic partners.

The company's goal is to serve what it sees as a massive but underaddressed target group: Asian women.

The new company, called Inex Innovate, aims by next year to introduce new tests for ovarian cancer and breast cancer in Asian women.

The firm's EpiSwitch test for blood-based diagnosis of prostate cancer will be evaluated as part of the ongoing PROSTAGRAM trial.

The company, which went public in 2017, generates all its revenues through its epigenetic biomarker research and development partnerships.

Oxford BioDynamics will work with Italian research institute Casa Sollievo della Sofferenza to identify blood-based biomarkers of autism spectrum disorder.

Participants aim to use predictive modeling to better understand epigenetic mechanisms, while encouraging the development of new technologies and therapies.

Oxford BioDynamics has developed a platform for discovering, evaluating, validating, and monitoring a unique class of epigenetic biomarkers.

Pages

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.